Articles related to ANTI-PSYCHOTICS

Explore the latest research on non-dopaminergic mechanisms for schizophrenia treatment, revealing innovative approaches that may lead to more effective and well-tolerated therapies.

The latest systematic review on olanzapine for schizophrenia treatment has defined a therapeutic reference range of 20-40 ng/mL, offering insight into optimal efficacy and tolerable levels. Explore the full study to understand how these findings can inform clinical practice and patient care.

This groundbreaking study from Northwestern Medicine unveils a surprising interaction of antipsychotic drugs with neurons, prompting a revision of our understanding of psychosis treatment and opening new pathways for more effective, safer drugs.

Study Reveals Different Effects of Antipsychotics on Weight Gain: Key Findings for Physicians A new study analyzed the impact of different antipsychotic medications on weight gain, emphasizing the importance of considering dose and specific drugs for individual patients. The study provides valuable insights for physicians to make informed decisions regarding antipsychotic use. Key Points: “Weight gain from medication is one of the most problematic adverse effects facing patients with serious mental illness… It can be a real barrier in getting people to take their meds.” Michel Sabé, MD, corresponding author

Understanding the Effects of Drugs with Depressive Symptom Side Effects on Patients with MDD Learn more about the complex interaction between the usage of specific drugs and the severity of depressive symptoms in people with major depressive disorder (MDD).

When atypical AMD is suspected, additional multimodal imaging and a more detailed medical history are required to establish the correct diagnosis. The medical history, clinical examination, and retinal imaging findings of a 69-year-old White man with a long-standing medical history of schizophrenia, bilateral visual decline, nyctalopia, and blurred vision were sufficient evidence for the doctors to establish a presumed diagnosis of thioridazine retinal toxicity. Although it is a rare diagnosis due to the introduction of newer medications, patients with an underlying psychiatric history and atypical retinal findings on examination may have been or are currently taking the culprit psychotropic medication.